ASH 2021
Pirtobrutinib, a non-covalent Bruton’s tyrosine kinase (BTK) inhibitor, showed promising efficacy in patients with ...
A fixed-duration combination of the first-generation Bruton tyrosine kinase (BTK) inhibitor ibrutinib and the ...
Second-line therapy comprising standard rituximab plus bendamustine and bortezomib was effective and well-tolerated as ...
The trial was conducted by Dr. Malin Hultcrantz and colleagues, and presented at the 2021 American Society of Hematology.
A phase II study presented at the 2021 Annual Meeting & Exposition of the American Society of Hematology, reported ...
The all-oral, once-daily, fixed-duration combination of ibrutinib and venetoclax demonstrated superior undetectable MRD ...
In the iStopMM (Iceland Screens, Treats, or Prevents Multiple Myeloma) study, researchers explored whether ...
These results were presented at the 2021 American Society of Hematology Annual Meeting.
The three-drug combination was previously investigated in the CASTOR trial.
The study’s results may lay the groundwork for the development of a patient-centered frailty index.
Brexucabtagene autoleucel (brexu-cel) has been implemented into standard MCL care since its 2020 FDA approval.
Researchers developed a virtual frailty assessment for older adults with hematologic malignancies and found no evidence ...
Nearly half of new diagnosed of multiple myeloma (MM) and non-Hodgkin lymphoma (NHL) are in patients over 75 years old.
This retrospective study reviewed charts of patients with MM initiating daratumumab from January 2018 to May 2020.
It is not clear if differences in diagnostic evaluation lead to differences in treatment strategies and survival outcomes.
Socioeconomic status (SES) accounted for disparities in survival time between Hispanic and non-Hispanic White patients ...
An analysis of data from the CoMMpass trial revealed no obvious differences in significant measures of genomic variation ...
Enrollment of ethnic minorities into academic clinical trials of multiple myeloma (MM) in the United Kingdom was below ...
A study of individuals with multiple myeloma (MM) revealed significant racial disparities in the prevalence of obesity ...
The analysis was a retrospective cohort analysis of 32 consecutive WM patients treated with ASCT.
Responses to the bispecific antibody were examined in patients with heavily pretreated relapsed/refractory multiple myeloma.
Tirabrutinib was designed to improve the safety and efficacy of ibrutinib with a more favorable toxicity profile.
Prevalence-corrected estimates for enrollment of Blacks were calculated via the participation to prevalence ratio.
Researchers discerned baseline demographics, symptoms, and survival outcomes of WM among different ethnic groups.
Researchers led by Nitin Jain, MD, of MD Anderson Cancer Center, enrolled eight patients with DLBCL RT in a phase II trial.
Researchers shared results from a prespecified interim analysis of TRANFORM, a global, phase III trial.
Ahead of the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition, the organization highlighted ...
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.